NCT07278310招募中不适用
STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)
MiRus1 个研究点 分布在 1 个国家目标入组 1,025 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,025
- 试验地点
- 1
- 主要终点
- All-cause mortality, all stroke and cardiovascular rehospitalization
研究概览
简要总结
To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.
详细描述
The primary objective is to assess the acute and long-term safety and efficacy of the Siegel THV device in adult subjects with symptomatic, severe native calcific aortic stenosis eligible for the transcatheter aortic valve replacement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are eligible for entry in this study if ALL the following conditions are met:
- •Age ≥ 18 years
- •Symptomatic, severe native calcific aortic stenosis in subjects at low, intermediate or high surgical risk AVA ≤ 1.0 cm2 or AVA index ≤ 0.6 cm2/m2 or Jet velocity ≥ 4.0 m/s or mean gradient ≥ 40 mmHg or dimensionless Index <0.25
- •New York Heart Association Functional Class ≥ 2
- •Requires aortic valve replacement and is indicated for TAVR as determined by the Heart Team (composed of an experienced interventional cardiologist and an experienced cardiac surgeon)
- •Eligible for transfemoral delivery of a TAVR
- •Native aortic annulus suitable for safe placement of Siegel 23mm, 26mm or 29 mm transcatheter heart valve. Preprocedural measurements by TTE and CT of aortic annulus area (23mm: 330- 440 mm2 , 26mm: 430-550 mm2, 29mm: 540-690 mm2)
- •Understands the study requirements and the treatment procedures and provides written informed consent
- •Subject agrees to complete all required scheduled follow-up visits.
排除标准
- •Subjects will be excluded for entry in this study if ANY of the following conditions are met:
- •Cardiac anatomy precluding safe placement of a transcatheter aortic valve.
- •Iliofemoral vessel characteristics (vessel diameter <5.5mm for smaller THV systems [20-26mm valve sizes] or <6.0mm for larger THV systems [29mm or larger valve sizes]) that would preclude safe placement of commercially available transcatheter aortic valves (SAPIEN 3 or Evolut)
- •Pre-existing prosthetic heart valve or ring except in the mitral position.
- •Unicuspid aortic valve
- •Severe aortic regurgitation (>3+)
- •Severe mitral or severe tricuspid regurgitation(>3+) requiring intervention.
- •Moderate to severe mitral stenosis.
- •Hypertrophic obstructive cardiomyopathy (HOCM)
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment.
- •Significant aortic disease including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5.5 cm or greater or ascending aortic aneurysm defined as maximal luminal diameter 5 cm or greater.
- •Evidence of an acute myocardial infarction ≤ 30 days before enrollment.
- •Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure
- •Blood dyscrasias as defined: leukopenia (WBC < 3000 cell/mL, anemia (Hgb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mL), history of bleeding diathesis or coagulopathy.
- •Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization
- •Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support within the past 30 days.
- •Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of enrollment
- •Need for emergency surgery for any reason
- •Ventricular dysfunction with left ventricular ejection fraction (LVEF) < 25% as measured by resting echocardiogram
- •Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
- •Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 30 days of enrollment
- •Renal insufficiency (eGFR < 30 ml/min per the Cockcroft-Gault formula) and/or renal replacement therapy, or end stage renal disease requiring chronic dialysis
- •GI bleeding within the past 3 months
- •Severe lung disease (FEV1 < 50% predicted) or currently on home oxygen
- •History of cirrhosis or any active liver disease
- •Significant abdominal or thoracic aortic disease (such as porcelain aorta, abdominal aortic aneurysm > 5.0 cm, severe calcification, aortic coarctation, etc.) that would preclude safe passage of the delivery system
- •Severe pulmonary hypertension (e.g., PA systolic pressure ≥ 2/3 systemic pressure)
- •A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, ticlopidine and clopidogrel, contrast media, nickel, cobalt ,chromium, titanium, molybdenum, rhenium, polyethylene materials.
- •Ongoing sepsis, including active endocarditis
- •BMI > 50 kg/m2
- •Subject refuses a blood transfusion
- •Life expectancy < 12 months due to associated non-cardiac co-morbid conditions
- •Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent
- •Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
- •Currently participating in an investigational drug or another investigational device trial
- •Subject is contraindicated for cardiac CT
- •Subject belongs to a vulnerable population (Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention).
研究组 & 干预措施
Treatment Arm
Experimental
Investigational Device- Siegel TAVR
干预措施: Siegel TAVR Device (Device)
Control Arm
Active Comparator
Commercially available TAVR device- Sapien TAVR or Evolute TAVR
干预措施: TAVR Device (Device)
结局指标
主要结局
All-cause mortality, all stroke and cardiovascular rehospitalization
时间窗: 1 Year
The primary endpoint is the composite of all-cause mortality, all stroke, and cardiovascular rehospitalization (valve-related or procedure-related per VARC-3) at 1 year.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
4 期
EMPagliflozin after Aortic Valve Replacement - the EMPAVR studyAortic stenosis2023-504731-40-01Rigshospitalet, Rigshospitalet206
终止
3 期
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)Aortic Valve StenosisNCT02817789University Hospital, Bordeaux50
进行中（未招募）
不适用
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility StudyAortic Stenosis SymptomaticNCT06680427MiRus30
招募中
不适用
To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic StenosisAortic Valve StenosisNCT04893603Chengdu Silara Meditech Inc.120
进行中（未招募）
不适用
Real-world Study on Fenestrated Stent for Thoracic Aortic DissectionNCT07268755Qingyou Meng320